Biological Age Predicts 90-Day Mortality in Advanced Cancer

NCT07035470 | Completed

• 1 other identifier: AEŞH-BADEK-2025-0149
• Study Type: observational
• Target: 1,615
• Locations: 1 country
• Sites: 1

Brief Summary

This retrospective study evaluates whether biological age, calculated using the PhenoAge model, predicts short-term outcomes in patients with advanced cancer who were hospitalized. The main goal is to investigate associations between biological age and short-term mortality, functional status (ECOG), comorbidity burden (mCCI), and length of hospital stay. All data were collected from medical records without any patient intervention.

Conditions

Advanced Solid Tumors Cancer; Hospitalizations

Keywords

Biological Age; PhenoAge; Advanced Cancer; Hospitalized Patients

Outcome Measures

Primary Outcomes (1)

• 90-Day All-Cause Mortality

  All-cause mortality within 90 days following the date of hospital admission (index hospitalization).

  Up to 90 days post-admission

Secondary Outcomes (1)

• Modified Charlson Comorbidity Index (mCCI)

  Baseline (Day of hospital admission)

Study Arms (1)

Hospitalized Advanced Cancer Patients

Patients hospitalized with advanced solid tumors (Stage III or IV) in the oncology clinic were retrospectively analyzed. Biological age was calculated using the PhenoAge model. Clinical outcomes such as mortality, ECOG score, mCCI, and length of stay were assessed.

Other: PhenoAge-Based Biological Age Assessment

Interventions

PhenoAge-Based Biological Age Assessment OTHER

Biological age was retrospectively calculated using the PhenoAge algorithm, based on nine routine laboratory parameters and chronological age. This model estimates phenotypic aging and was used to predict short-term outcomes including mortality, functional status, comorbidity burden, and hospital length of stay. No new intervention was administered; all data were collected from existing medical records.

Hospitalized Advanced Cancer Patients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study includes adult patients (≥18 years old) with advanced-stage solid tumors who were hospitalized at Etlik City Hospital, Turkey, between November 5, 2022, and December 31, 2024. Only patients with at least 48 hours of hospitalization and complete laboratory data necessary for PhenoAge calculation were included. The study population represents a real-world sample of hospitalized cancer patients at elevated risk of short-term adverse outcomes.

You may qualify if:

• Hospitalized in the Medical Oncology Department between November 5, 2022, and December 31, 2024
• Histologically confirmed advanced-stage (stage III-IV) solid tumors
• Age ≥18 years
• Hospital stay of at least 48 hours
• Actively receiving chemotherapy or received it within the last 6 months
• Availability of all 9 required laboratory tests (albumin, creatinine, glucose, CRP, lymphocyte %, MCV, RDW, ALP, WBC) for PhenoAge calculation during the first admission

You may not qualify if:

• Elective hospitalizations (e.g., planned chemotherapy, biopsy)
• Patients who died during the first admission
• Missing required laboratory parameters
• ICU patients and unconscious patients

Sponsors & Collaborators

• Ankara Etlik City Hospital: lead

Study Sites (1)

Etlik City Hospital

Ankara, Yenimahalle, 06210, Turkey (Türkiye)

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: June 16, 2025
• First Posted: June 25, 2025
• Study Start: November 5, 2022
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: June 29, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)